Clinical research of multisystem inflammatory syndrome in children.
10.3760/cma.j.cn112140-20230805-00081
- Author:
Ruo Hang WENG
1
;
Wei Ying ZHAO
2
;
Ting Yan HE
1
;
Xiao Lin LI
3
;
Xiao Qing LI
4
;
Dong Mei ZHAO
5
;
Yun Kun HAN
6
;
Ping ZENG
7
;
Xue Mei TANG
8
;
Xiao Chuan WU
9
;
Li LIU
2
;
Jun YANG
1
Author Information
1. Department of Rheumatology and Immunology, Shenzhen Children's Hospital, Shenzhen 518038, China.
2. Department of Internal Medicine, Tianjin Children's Hospital (Children's Hospital of Tianjin University), Tianjin Key Laboratory of Birth Defects for Prevention and Treatment, Tianjin 300074, China.
3. Department of Pediatrics, Boai Hospital of Zhongshan, Zhongshan 528400, China.
4. Department of Rheumatology and Immunology, Xi'an Children's Hospital, Xi'an 710003, China.
5. Department of Rheumatology and Immunology, Urumqi Children's Hospital, Urumqi 830002, China.
6. Department of Rheumatology and Immunology, Children's Hospital of Changchun, Changchun 130061, China.
7. Department of Rheumatology and Immunology, Guangzhou Women and Children Medical Center, Guangzhou 510120, China.
8. Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China.
9. the Children's Medical Center, the Second Xiangya Hospital, Central South University, Changhai 410011, China.
- Collective Name:Chinese Alliance of Pediatric Rheumatic and Immunologic Diseases
- Publication Type:Journal Article
- MeSH:
Male;
Child;
Female;
Humans;
Immunoglobulins, Intravenous/therapeutic use*;
Blood Coagulation;
COVID-19;
China/epidemiology*;
Connective Tissue Diseases;
Coronary Aneurysm;
Fever;
Systemic Inflammatory Response Syndrome/therapy*
- From:
Chinese Journal of Pediatrics
2023;61(12):1086-1091
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical characteristics of children with multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 in China, and to improve the understanding of MIS-C among pediatricians. Methods: Case series study.Collect the clinical characteristics, auxiliary examinations, treatment decisions, and prognosis of 64 patients with MIS-C from 9 hospitals in China from December 2022 to June 2023. Results: Among the 64 MIS-C patients, 36 were boys and 28 were girls, with an onset age being 2.8 (0.3, 14.0) years. All patients suffered from fever, elevated inflammatory indicators, and multiple system involvement. Forty-three patients (67%) were involved in more than 3 systems simultaneously, including skin mucosa 60 cases (94%), blood system 52 cases (89%), circulatory system 54 cases (84%), digestive system 48 cases (75%), and nervous system 24 cases (37%). Common mucocutaneous lesions included rash 54 cases (84%) and conjunctival congestion and (or) lip flushing 45 cases (70%). Hematological abnormalities consisted of coagulation dysfunction 48 cases (75%), thrombocytopenia 9 cases (14%), and lymphopenia 8 cases (13%). Cardiovascular lesions mainly affected cardiac function, of which 11 patients (17%) were accompanied by hypotension or shock, and 7 patients (12%) had coronary artery dilatation.Thirty-six patients (56%) had gastrointestinal symptoms, 23 patients (36%) had neurological symptoms. Forty-five patients (70%) received the initial treatment of intravenous immunoglobulin in combination with glucocorticoids, 5 patients (8%) received the methylprednisolone pulse therapy and 2 patients (3%) treated with biological agents, 7 patients with coronary artery dilation all returned to normal within 6 months. Conclusions: MIS-C patients are mainly characterized by fever, high inflammatory response, and multiple organ damage. The preferred initial treatment is intravenous immunoglobulin combined with glucocorticoids. All patients have a good prognosis.
